publication date: Apr. 7, 2017
Issue 14 - Apr. 7, 2017
  • Biden: Trump’s cuts would set back cancer research by 15 years

    A budget proposed by President Donald Trump would set NIH and biomedical research back 15 years, said former Vice President Joe Biden, addressing members of the American Association for Cancer Research on April 3.

  • Biden pledges to remain a player in oncopolitics, plans to launch cancer initiative

    Former Vice President Joe Biden said he plans to launch the Biden Cancer Initiative, which would focus on data sharing, quality of cancer care, patient access, and increasing participation in clinical trials.

  • Guest Editorial

    Oregon’s Death with Dignity Act: Learning from 18 years of data on physician-aided dying

    Oncologists must confront end-of-life issues on a nearly daily basis. Our approach to the potential death of a patient may change over time, however, depending on the patients’ diagnosis and stage, where those patients are in their treatment plan, and, of course, what the patients’ wishes are. When feasible, our primary goal is to prevent death from cancer, and when we cannot achieve that, we try to delay death as long as we can. When dying seems inevitable, we do our best to make it as comfortable as possible.

  • In Brief

    • Michael Caligiuri starts term as AACR president
    • SU2C names researchers to $12 Million “Dream Team” on colorectal cancer
    • BMS gives SU2C to $7.5 million to fund immuno-oncology grants
    • David Sabatini wins FNIH Lurie Prize in Biomedical Sciences
    • Jennifer Pietenpol named chief scientific advisor for Susan G. Komen
    • Mark Soberman becomes president of ACCC
    • Biocept, OHSU announce collaboration to increase clinical use of liquid biopsy
    • Sylvester, Syapse to launch precision medicine initiative
    • Invitae starts Patient Insights Network to enable sharing of health information
    • LLS Commits $4 Million to Forty Seven Inc.
    • NCCN imaging appropriate use criteria published for 13 additional guidelines
  • Drugs and Targets

    • Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced NSCLC
    • FDA accepts for review the application of Ibrutinib for cGVHD after failure of systemic therapy
    • Amgen seeks to expand XGEVA indications to multiple myeloma in the US, Europe
    • RedHill receives orphan drug designation for Yeliva
    • ESSA Pharma receives $1.2 million grant payment from CPRIT
    • Oncora Medical cooperate on precision radiation oncology

Copyright (c) 2017 The Cancer Letter Inc.